Research analysts issue Puma Biotechnology, Inc.’s 2025 earnings forecasts. (NASDAQ:PBYI)

Puma Biotechnology, Inc. (NASDAQ:PBYI – Free Report) – Equities research analysts at Zacks Research lowered their FY2025 earnings per share (EPS) estimates for shares of Puma Biotechnology in a research report issued on Thursday, September 26th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings per share of $0.19 for the year, down from their prior estimate of $0.22. The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.25 per share.

Puma Biotechnology (NASDAQ:PBYI – Get Free Report ) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.01. The company had revenue of $47.10 million during the quarter, compared to analysts’ expectations of $43.99 million. Puma Biotechnology had a net margin of 4.01% and a return on equity of 18.36%. During the same period last year, the business earned $0.05 EPS.

PBYI has been the subject of a number of other reports. HC Wainwright restated a “buy” rating and set a $7.00 price objective on shares of Puma Biotechnology in a research note on Friday, August 2nd. StockNews.com cut Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 13th.

Check out our latest research report on PBYI

Biotech stock Puma rose 0.8%

Shares of Puma Biotechnology stock opened at $2.58 on Monday. The company has a current ratio of 1.32, a quick ratio of 1.23, and a debt-to-equity ratio of 0.90. Puma Biotechnology has a 1 year low of $2.13 and a 1 year high of $7.73. The company has a fifty day simple moving average of $2.93 and a 200 day simple moving average of $3.82. The company has a market cap of $126.55 million, a P/E ratio of 7.82 and a beta of 1.09.

Hedge funds influence Puma biotech

Institutional investors and hedge funds have recently modified their holdings of the stock. Frazier Life Sciences Management LP boosted its holdings in shares of Puma Biotechnology by 8.7% during the second quarter. Frazier Life Sciences Management LP now owns 3,062,558 shares of the biopharmaceutical company’s stock worth $9,984,000 after buying an additional 246,264 shares during the period. The Manufacturers Life Insurance Company acquired a new stake in Puma Biotechnology in the second quarter valued at about $58,000. Affinity Asset Advisors LLC bought a new stake in shares of Puma Biotechnology in the second quarter valued at about $815,000. Squarepoint Ops LLC grew its position in shares of Puma Biotechnology by 17.7% in the second quarter. Squarepoint Ops LLC now owns 71,391 shares of the biopharmaceutical company’s stock valued at $233,000 after buying an additional 10,757 shares in the last quarter. Finally, Great Point Partners LLC raised its stake in shares of Puma Biotechnology by 10.6% in the second quarter. Great Point Partners LLC now owns 1,486,544 shares of the biopharmaceutical company’s stock worth $4,846,000 after purchasing an additional 142,916 shares during the period. 61.29% of the shares are currently held by institutional investors and hedge funds.

Insider buying and selling

In other Puma Biotechnology news, CEO Alan H. Auerbach sold 18,885 shares of the stock in a transaction dated Tuesday, July 2nd. The shares were sold at an average price of $3.27, for a total value of $61,753.95. Following the completion of the sale, the chief executive officer now owns 7,085,435 shares in the company, valued at $23,169,372.45. The sale was disclosed in a filing with the SEC, which is accessible via this hyperlink. In other Puma Biotechnology news, CEO Alan H. Auerbach sold 18,885 shares of the business’s stock in a transaction that occurred on Tuesday, July 2nd. The stock was sold at an average price of $3.27, for a total value of $61,753.95. Following the sale, the chief executive officer now owns 7,085,435 shares in the company, valued at $23,169,372.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available via this link. Also, Director Michael Patrick Miller sold 23,358 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $3.49, for a total value of $81,519.42. Following the completion of the sale, the director now directly owns 47,000 shares of the company’s stock, valued at $164,030. The disclosure for this sale can be found here. Over the last three months, insiders have sold 82,263 shares of company stock worth $286,469. Insiders own 23.70% of the company’s shares.

About Puma Biotechnology

(Get a free report)

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on developing and commercializing products to improve cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib, which is used to treat adult patients with early-stage HER2-overexpressing/amplified breast cancer; and HER2-positive advanced or metastatic breast cancer when combined with capecitabine.

See Also

Get news and reviews for Puma Biotechnology Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Puma Biotechnology and related companies with MarketBeat.com’s FREE daily email newsletter.